Previous Article | Next Article ![]()
Infection and Immunity, April 2002, p. 2198-2205, Vol. 70, No. 4
0019-9567/02/$04.00+0 DOI: 10.1128/IAI.70.4.2198-2205.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.
and J. N. Engel1,2,3*
Departments of Medicine,1 Microbiology and Immunology,2 Cardiovascular Research Institute, University of California, San Francisco, San Francisco, California 941433
Received 24 July 2001/ Returned for modification 25 September 2001/ Accepted 9 January 2002
|
|
|---|
|
|
|---|
ExoT exhibits GAP activity toward Rho, Rac, and Cdc42 in vivo Strains and plasmids that we used are listed (Table 1). ExoT was PCR amplified from PA103 genomic DNA using primers BAKA18 (5' GCGGGTACCATGGATATTCAATCATCTCAGCAG 3') and BAKA19 (5' GGCGGTACCTCAGGCCAGGTCGAGG 3'). The resulting fragment contains KpnI sites flanking the ExoT coding sequence, introduces an NcoI site at the ATG start codon, and changes the second amino acid of ExoT from aspartate to histidine. The PCR product was subcloned into pCruz Myc-B (Santa Cruz Biotechnology), creating a gene encoding a fusion protein with an amino-terminal Myc epitope tag under control of the cytomegalovirus (CMV) promoter (pMyc-T). Mammalian expression vectors expressing ExoT mutated at Arg149 to either glycine (R149G) or lysine (R149K) were constructed by an identical strategy, using pBK151 or pBK162 as template DNA for PCR amplifications (pMyc-T[R149G] and pMyc-T[R149K], respectively). The predicted sequences of these constructs were confirmed by nucleotide sequencing (University of California at San Francisco Biomolecular Resource Center sequencing facility). To assay the GAP activity of wild-type ExoT in the absence of other bacterial proteins, 5 x 105 HeLa cells (grown in DME-H21 [University of California at San Francisco Cell Culture Facility] supplemented with 10% fetal calf serum [Gibco] at 37°C in 5% CO2) were plated to 10-cm-diameter tissue culture dishes 24 h prior to transfection with 2 µg of pMyc-T in the presence of Effectene (Qiagen). Mock transfections were carried out in parallel. Cells were harvested 12 to 14 h after transfection, at which time Myc-tagged ExoT was detectable by indirect immunofluorescence in approximately 25% of cells (see below). The amount of RhoA-GTP present in mock- and ExoT-transfected cells was determined by selectively affinity precipitating GTP-bound RhoA with the rhotekin binding domain fused to glutathione reductase (GST-TRBD) and coupled to glutathione-Sepharose 4B (Amersham Pharmacia), a method originally described by Ren et al. (28). Activity of the coupled GST-TRBD reagent was assayed each time that reagent was prepared by demonstrating complete affinity precipitation of RhoA activated by cytotoxic necrotizing factor 1 treatment of Madin-Darby canine kidney (MDCK) cells, while specificity of the reagent for the GTP-bound form of RhoA was demonstrated by its inability to affinity precipitate the dominant negative allele of RhoA, RhoAN19, from MDCK cells induced to express this myc-tagged protein (20) (data not shown). Cell lysates were prepared as described previously (20), and total protein was determined (Pierce BCA Assay kit). Twenty microliters of each lysate was set aside ("total"); 500 µl was incubated with GST-TRBD coupled to glutathione-Sepharose 4B beads, which allowed selective precipitation of RhoA-GTP ("GTP-bound"). Total and GTP-bound samples were loaded in their entirety onto 13% polyacrylamide gels, subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and Western blotted to polyvinylidene difluoride (Millipore). Membranes were blocked with 5% (wt/vol) dry milk, incubated with anti-RhoA antibody (1:200) (Santa Cruz Biotechnology) followed by goat anti-mouse immunoglobulin G (IgG)-horseradish peroxidase conjugate (1:2,000) (Bio-Rad), developed using ECL Plus (Amersham), and exposed to Biomax ML film (Kodak). The amount of RhoA in each sample was approximated by scanning films and determining the density of scanned bands using the IPLabGel program. The amount of GTP-bound versus total RhoA was calculated and normalized to the amount present in mock-transfected cells. As seen in Fig. 1, ExoT-transfected cells showed no detectable RhoA-GTP in this assay, while approximately 5% of RhoA was present in the GTP-bound form in mock-transfected cells. GAP activity toward RhoA was absolutely dependent on the presence of Arg149, as cells transfected with 2 µg of pMyc-T(R149G) or pMyc-T(R149K) (expression constructs identical to pMyc-T except for a single amino acid change at position 149 of ExoT) showed amounts of Rho-GTP comparable to those observed in mock-transfected cells (Fig. 1).
|
View this table: [in a new window] |
TABLE 1. Bacterial strains and plasmidsa
|
![]() View larger version (52K): [in a new window] |
FIG. 1. Cells transfected with wild-type ExoT but not with ExoT(R149G) or ExoT(R149K) show loss of GTP-bound RhoA, Rac1, and Cdc42. HeLa cells were transfected with pMycB-LacZ (Mock), pMycB-T, pMycB-T(R149K), or pMycB-T(R149G) 12 h prior to lysis and determination of total and GTP-bound RhoA, Rac1, and Cdc42 levels as described in the text. (Twenty microliters of lysate was analyzed for total RhoA, Rac1, or Cdc42, while 500 µl of lysate was used in the affinity precipitations.) The experiments shown are characteristic of three or four independent assays. Italicized numbers indicate the fraction of each GTPase present in the GTP-bound form as normalized to mock-transfected cells.
|
Activation of RhoA is sufficient to increase P. aeruginosa internalization by epithelial cells; however, activation of neither Rac1 nor Cdc42 promotes P. aeruginosa internalization (20). We therefore asked whether the anti-internalization factor ExoT might exhibit specificity toward RhoA in vivo and show no significant activity toward Rac or Cdc42 when expressed in epithelial cells. Using the Cdc42/Rac interactive binding (CRIB) domain of hPak3 fused to GST as an affinity precipitation reagent selective for the GTP-bound forms of Rac1 and Cdc42 (3), we were able to precipitate Rac1-GTP and Cdc42-GTP from transfected cells in a method analogous to that described above for Rho-GTP determinations. The GST-CRIB reagent's activity and specificity were confirmed by demonstrating that this reagent selectively precipitated the constitutively active alleles of Rac1 (myc-Rac1V12) and Cdc42 (myc-Cdc42V12) from stably transfected MDCK cell lines expressing these proteins but was unable to pull down the dominant negative allele myc-RacN17 or myc-Cdc42N17 (20) (data not shown). As seen in Fig. 1, transfected cells exhibited diminished levels of both Rac-GTP and Cdc42-GTP compared to mock-transfected cells, demonstrating that all three GTPases serve as in vivo substrates for ExoT. The decreases in Rac-GTP and Cdc42-GTP levels were again dependent on the presence of arginine at position 149 in ExoT, as cells that were transfected with ExoT mutated at position 149 to glycine or lysine showed minimal changes in Rac1-GTP or Cdc42-GTP levels compared to mock-transfected cells (Fig. 1).
Decreased expression levels of transfected ExoT(R149G) or ExoT(R149K) relative to the wild-type protein could account for our inability to observe GAP activity following transfection of these proteins into HeLa cells. Indirect immunofluorescence, however, confirmed that both T(R149G) (96 of 319, 30% positive) and T(R149K) (52 of 208, 25% positive) were strongly expressed in the same proportion of HeLa cells as the wild-type protein (108 of 438, 25% positive) at 12 to 14 h posttransfection. As was shown previously, ExoT mutated at Arg149 to Gly or Lys is detected in mammalian cells following translocation without evidence of increased protein degradation or instability (10).
Bacterially translocated ExoT exhibits GAP activity toward Rho, Rac, and Cdc42 in vivo.
Expression of ExoT in transfected mammalian cells results in decreased levels of GTP-bound RhoA, Rac1, and, to a lesser extent, Cdc42. Thus, the specificity of ExoT's GAP activity in eukaryotic cells parallels that determined in vitro for purified ExoT and substrates (21). To determine whether other bacterial proteins may modify the GAP activity of ExoT, we assayed the in vivo GAP activity associated with infection by strains expressing wild-type ExoT. These experiments were carried out using PA103
U, a strain carrying an in-frame deletion within the exoU gene, so that cell necrosis caused by this type III secreted toxin would not interfere with these assays (10). HeLa cells (n = 106) were plated to 10-cm-diameter dishes 48 h prior to infection with PA103
U at a multiplicity of infection (MOI) of 25 to 50. Cells were lysed at 0, 1, and 2 h following bacterial infection, and GTP-bound RhoA, Rac1, and Cdc42 were detected as described above. GTP-bound levels of all three Rho family members decreased with time, demonstrating that ExoT had GAP activity toward all of these proteins when translocated into host cells in physiological amounts and in the context of other bacterial proteins (Fig. 2). As found in the transfected cells, the presence of arginine at position 149 was required for GAP activity, as infection with PA103
U/T(R149K) or PA103
U/T(R149G) did not decrease GTP-bound Rho, Rac, or Cdc42 levels (Fig. 3). Infected cells were examined by phase-contrast microscopy prior to lysis, allowing us to confirm that the characteristic changes in cell morphology associated with infection were present in most cells by 2 h postinfection (data not shown). Thus, as previously reported, PA103
U-infected cells showed cell body rounding; cells infected by bacteria carrying either Arg149 point mutation showed cytoplasmic retraction and cell body elongation; and cells infected with PA103
U
T were indistinguishable from uninfected control cells (10).
![]() View larger version (58K): [in a new window] |
FIG. 2. Infection with ExoT expressing PA103 U results in loss of GTP-bound RhoA, Rac1, and Cdc42. HeLa cells were infected with PA103 U (MOI = 25 to 50) 0, 1, or 2 h prior to lysis, and determination of total and GTP-bound RhoA, Rac1, and Cdc42 levels was carried out as described in the text. Duplicate samples are shown for each time point. The experiments shown are representative of two or three independent assays.
|
![]() View larger version (65K): [in a new window] |
FIG. 3. Bacterially translocated ExoT(R149G) and ExoT(R149K) do not cause the loss of GTP-bound RhoA, Rac1, or Cdc42 in infected cells. HeLa cells were infected with PA103 U (wt T), PA103 U T ( T), PA103 U/T(R149K) [T(RK)], or PA103 U/T(R149G) [T(RG)] at an MOI of 25 to 50 for 2 h prior to cell lysis. Uninfected cells (uninf) were processed in parallel as a control. Total and GTP-bound RhoA, Rac1, and Cdc42 were detected as described in the text. The experiments shown are representative of two or three independent assays.
|
![]() View larger version (62K): [in a new window] |
FIG.4. Cells transfected with wild-type ExoT but not ExoT(R149G) or ExoT(R149K) exhibit stress fiber loss and cell rounding. HeLa cells plated on coverslips were transfected with pMyc-T (A to D), pMyc-T(R149G) (E to F), or pMyc-T(R149K) (G to H) 10 to 14 h prior to fixation. All samples were stained with anti-Myc MAb 9E10 (green) to identify cells expressing ExoT, Texas red-phalloidin (red) to visualize the actin cytoskeleton, and DAPI (blue) to visualize nuclei. Samples were imaged on a Nikon Eclipse E800 microscope equipped with DAPI, fluorescein isothiocyanate, and rhodamine filter sets using a 100x objective, captured with a Spot charge-coupled device camera (Diagnostic Instruments, Inc.) using Spot Advanced 3.0.4 software, pseudocolored, and assembled into figures using Adobe Photoshop 5.0. Panels A, C, E, and G show triply stained cells; panels B, D, F, and H show phalloidin staining only. In panels A to D, cells expressing ExoT show clear loss of stress fibers; cells transfected with either point mutant (E to H) maintain normal stress fiber morphology.
|
![]() View larger version (56K): [in a new window] |
FIG. 5. Expression of RhoAV14 but not of Rac1V12 prevents ExoT-mediated actin cytoskeleton disassembly and cell rounding. HeLa cells plated on coverslips were transfected with 1 µg of either pMyc-RhoAV14 (A and B) or pMyc-Rac1V12 (C and D) for 14 h prior to fixation; 1 µg of pHA-T was cotransfected in panels B and D. All samples were stained with anti-Myc MAb 9E10 (green) and anti-HA MAb 3F10 (red) to identify cells expressing RhoAV14 or Rac1V12 and ExoT, respectively. The actin cytoskeleton was visualized with Bodipy 650/655-conjugated phalloidin (blue). Cells were imaged with a Bio-Rad 1024 confocal microscope equipped with KrAg and HeNe lasers and fluorescein isothiocyanate, Texas red, and Cy5 filter sets using a 60x objective. Z sections were acquired sequentially and processed using NIH Image 1.62b software and were then merged and pseudocolored in Adobe Photoshop 5.0. Cells doubly transfected with ExoT and RhoAV14 (B), which appear yellow, maintained a spread-out shape and showed some stress fibers; cotransfection with Rac1V12, however, did not prevent cell rounding and complete stress fiber loss (yellow-stained cells, panel D).
|
Recently, several groups have examined the in vitro and in vivo specificities of YopE. In vitro, YopE shows activity toward purified RhoA, Rac1, and Cdc42 (4, 30). In vivo activity toward RhoA and Rac1 has also been indirectly demonstrated, by showing that expression of a constitutively active allele of RhoA, RhoAV14, is sufficient to block actin stress fiber loss associated with YopE-expressing Y. pseudotuberculosis, while expression of constitutively active Rac1V12 inhibits YopE-dependent antiphagocytosis (4). These results are in apparent disagreement with a recent study by Andor et al. (1), where YopE was reported to inhibit ruffle formation following bradykinin stimulation of endothelial cells (the consequence of indirect Rac1 activation by Cdc42) but was unable to inhibit the direct activation of Cdc42, Rac1, or RhoA in response to bradykinin, sphingosine-1-phosphate, or thrombin stimulation, respectively, as assayed by microspike (Cdc42), ruffle (Rac1), or stress fiber formation (RhoA). The authors suggest that their findings indicate exquisite specificity of YopE toward Rac1 in vivo; however, it may also be that bacterially translocated YopE is present in the treated cells in too small an amount or too restricted a localization to overcome the stimulus presented by these pharmacologic activators of the Rho family GTPases.
P. aeruginosa ExoS has also undergone a recent examination of its in vivo activity toward Rho family GTPases. By assaying the distribution of GFP-Rac1 and GFP-Cdc42 fusion proteins, Krall et al. have demonstrated that the GAP domain of ExoS causes a relocalization of Rac1 and Cdc42 from the plasma membrane to the cytosol (22). As GTP-bound Rac1 and Cdc42 localize to the membrane, while GDP-bound Rac1 and Cdc42 are cytosolic, this suggests that the GAP domain of ExoS converts these two GTPases to the inactive form in vivo. RhoA also appeared to be a target of the ExoS GAP domain in vivo, as dominant active RhoA (RhoAQ63E) expression was required to prevent stress fiber loss in cells also transfected with the ExoS GAP domain (22). Thus, ExoS appears to exhibit GAP activity toward RhoA, Rac1, and Cdc42 in vivo as well as in vitro, much as we report here for ExoT.
Unlike YopE, ExoS, and ExoT, the Salmonella enterica serovar Typhimurium GAP SptP specifically activates GTP hydrolysis in vitro by Rac1 and Cdc42 and does not show appreciable GAP activity toward RhoA (8). This may reflect that the biological role of SptP in S. enterica serovar Typhimurium invasion is different from that proposed for the Yersinia and Pseudomonas GAPs. These latter organisms are thought to use their GAPs to block internalization by a wide variety of eukaryotic cells (professional and nonprofessional phagocytes). Conversely, S. enterica serovar Typhimurium possesses a type III secretion system (SPI 1) dedicated to promoting bacterial invasion of multiple cell types (9, 14) and translocates an effector, SopE, that activates Rac1 and Cdc42 and results in membrane ruffling and S. enterica serovar Typhimurium internalization (16). SptP, therefore, does not function to block invasion per se but rather returns the host cell cytoskeleton to baseline, presumably by inactivating Rac1 and Cdc42.
Though other bacterial toxins covalently modify their eukaryotic targets to activate (e.g., E. coli cytotoxic necrotizing factor 1) (24, 29) or inactivate them (e.g., Clostridium difficile toxin B) (19), a toxin such as ExoT can only shift the equilibrium between the active, or GTP-bound, form of a Rho family GTPase and the inactive, GDP-bound, form to favor the latter. Thus, the effect of such a protein is most visible on cells that are carrying out a task requiring continuous or repeated activation of a GTPase. The phenotypes that we have observed for ExoT fall into such a category. For example, the infection of epithelial cells with bacteria expressing wild-type ExoT (PA103
U) is sufficient to block cell migration in an in vitro wound closure model (11), a process that is known to require Rac1 and RhoA activation (26). Infection with mutants lacking wild-type ExoTPA103
U
T,
U/T(R149K), or
U/T(R149G)does not affect wound closure. Likewise, tight junctions can be disrupted by infection with PA103
U but not by infection with PA103
U
T (Kazmierczak and Engel, unpublished observations); the maintenance of tight junctions requires RhoA and Rac1 activation (18).
Lastly, it is clear that the enzymatic activity of ExoT toward the Rho family GTPases is absolutely dependent upon Arg149, as has been demonstrated for other bacterial GAPs, including P. aeruginosa ExoS (12, 22) and Y. enterocolitica YopE (4). The observation that bacterial strains carrying point mutations at Arg149 of ExoT are internalized to an intermediate extent, compared to strains with a deletion of ExoT versus strains expressing wild-type ExoT, suggests that bacterial GAP activity toward the Rho family GTPases accounts for only part of ExoT's anti-internalization activity (10). Studies to determine what roles other domains of ExoT play in this process are currently under way.
This work was supported by NIH grants AI 01636 (B.I.K.) and AI 42806 (J.N.E.). J.N.E. is a Career Investigator of the American Lung Association.
Present address: Department of Internal Medicine, Yale University, New Haven, CT 06520-8022. ![]()
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»